In general, the distribution of each indicator was similar in SGLT2i-related AEs and IMEs. For SGLT2i-related IMEs, monotherapy (94.99%) accounted for a much larger proportion than combination therapy, with canagliflozin constituting nearly half (48.26%). The vast majority of reports cited SGLT2i as the primary suspect drug (94.55%).
by A Acevedo 2024Journal list menu The recommendations. This appraisal compared the differences between SGLT2i, and against other oral diabetes medications.
When Trulicity is added to existing metformin and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued. SGLT2i When Trulicity is added to existing metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy, the current dose of metformin and/or SGLT2i can be continued.
Recommendation for addition of an SGLT2i (or GLP-1RA where SGLT2i is not tolerated or contraindicated) to other glucose lowering medication(s) in adults
Antihyperglycemic medication use was assessed on the drug class level including metformin, sulfonylureas, thiazolidinediones, SGLT2i
o SGLT2i with evidence of reducing HF and/or CKD progression (empagliflozin The following chart is a list of oral and injectable diabetes medications
by GV de Cos 2024 Cited by 3Euglycemic DKA is a rare and dangerous adverse effect of SGLT2i type drugs. The use of SGLT2i is indicated only in type 2 diabetics; its use
While I've been hard on newer medications like SGLT2i for their list of issues to navigate. The most common of these being genital
by A Paul 2024 Cited by 2Sodium-glucose co-transporter-2 inhibitors (SGLT2is), commonly referred to as the flozin group of drugs List J. Dapagliflozin a
Comments